about
Aptamers: A Feasible Technology in Cancer ImmunotherapyA regular thymine tetrad and a peculiar supramolecular assembly in the first crystal structure of an all-LNA G-quadruplexDirect validation of aptamers as powerful tools to image solid tumorAllosteric DNA nanoswitches for controlled release of a molecular cargo triggered by biological inputs.DNA aptamer evolved by cell-SELEX for recognition of prostate cancer.Nanotechnology for the detection and kill of circulating tumor cells.EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex.Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth.Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cellsAptamers as a novel tool for diagnostics and therapy.EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial CancerQuick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cellsIn vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticlesNucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex.Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP MiceAptamer-based therapeutics: new approaches to combat human viral diseasesSurvivin signaling in clinical oncology: a multifaceted dragon.Aptamer-dendrimer bioconjugate: a nanotool for therapeutics, diagnosis, and imaging.The application of aptamers in cancer research: an up-to-date review.In vitro selection of BNA (LNA) aptamers.Plasma and cellular pharmacokinetic considerations for the development and optimization of antitumor block copolymer micelles.Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery.A strain-promoted alkyne-azide cycloaddition (SPAAC) reaction of a novel EpCAM aptamer-fluorescent conjugate for imaging of cancer cells.Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer.Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.'Smart' nanoparticles as drug delivery systems for applications in tumor therapy.The implications and mechanisms of the extra-nuclear nucleolin in the esophageal squamous cell carcinomas.Multimodal iron oxide (Fe3O4)-saturated lactoferrin nanocapsules as nanotheranostics for real-time imaging and breast cancer therapy of claudin-low, triple-negative (ER(-)/PR(-)/HER2(-)).Recent applications of the combination of mesoporous silica nanoparticles with nucleic acids: development of bioresponsive devices, carriers and sensors.An on-chip Cell-SELEX process for automatic selection of high-affinity aptamers specific to different histologically classified ovarian cancer cells.Aptamers: a promising tool for cancer imaging, diagnosis, and therapy.Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy.Inhibition of Influenza Virus Replication by DNA Aptamers Targeting a Cellular Component of Translation Initiation.Aptamers as both drugs and drug-carriers.Fundamentals of affinity cell separations.Targeting the polyadenylation factor EhCFIm25 with RNA aptamers controls survival in Entamoeba histolytica.
P2860
Q26740303-CF3D3C06-9EC3-4A6E-9078-77555DE19CB6Q27689082-3CE8662B-EB37-41D5-A115-5A2AC9F2778EQ33632641-D4B9AEA4-A6DC-4BC2-88AD-B56FF9D850DAQ33749685-CC754FF8-2508-4004-B35B-E917C8A247DEQ33793416-38C5C0EA-3272-4FC2-AD0C-26584FC45F42Q34241179-C15475F6-B925-4009-9C2F-5B419307F9CFQ35018628-3A651239-E153-4303-94DF-43452B90EE18Q35148896-BE0A3C0F-EB5E-4483-9928-86661204E5F8Q35335653-B35C7BEC-B33C-445B-982E-B90D024A4604Q35552275-16B13EF9-821F-4845-9AC2-51632656B5EFQ35691811-F328E4C5-C159-44F9-A10D-A3A052B7BA85Q36117908-76C9ECD7-3BFC-496C-A4A4-CF09DA72E755Q36289257-F4F5DE89-1753-4631-9EB9-91913FF46B01Q36907845-AE081D8D-68D9-4519-9E0B-4AE07EDA429FQ37219900-041FB37D-BD0A-4D72-9578-4D1B239D4D0CQ37415958-688750F5-B91A-466F-912E-77616036639BQ38017923-ECDCD7E6-DFD6-4E79-9F90-65733BC9B014Q38035033-D0AEAA03-1C1F-4F2B-9911-4C72E7A7CC6BQ38087391-FB8078E2-2070-4F09-A060-745274F67197Q38138569-8492C9FD-8B39-45DF-8EFE-2756B96EA812Q38248809-AF25EF74-2D90-45F2-970B-02D8F32A1E37Q38300295-212DCBE9-17D9-4109-B434-974A312FA39DQ38305909-D84296E3-B8DF-4B74-BDE5-0B3BFDDA8493Q38319509-A779B070-F3F2-4E1C-B33B-B3FB103A0A84Q38491805-F5E97195-B623-4232-88F5-2FBB9ECEE8EFQ38550886-A1C6E0C2-E7AF-4342-A10D-60D4C357C5B4Q38915468-E753488E-5ECE-4579-8221-E5289F79C315Q38918835-CB5095E2-0F6C-4EDE-B853-499DA35110F1Q39096024-251B81AE-17DE-445B-A7BF-D0E1D02C1F4CQ39141922-E28B2EAE-03F3-4DDF-818B-EA1C4E1C94A4Q39558334-DEF74A11-E056-4CF5-8FA2-EA75DE547E30Q39596768-A7E4B3F6-6528-45C5-973B-B8633E4303E5Q40718042-69415B40-5185-4895-AF6B-A5D277412C7DQ42236644-BB0D50F1-30F4-45A5-9CEE-04BE30297EC1Q48272854-986F86F3-6DAB-4DEF-A62C-F4D3ABA071D7Q52597741-07503FDA-AAA2-4497-82FC-DCB470972B85
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Chimeric aptamers in cancer cell-targeted drug delivery
@en
Chimeric aptamers in cancer cell-targeted drug delivery.
@nl
type
label
Chimeric aptamers in cancer cell-targeted drug delivery
@en
Chimeric aptamers in cancer cell-targeted drug delivery.
@nl
prefLabel
Chimeric aptamers in cancer cell-targeted drug delivery
@en
Chimeric aptamers in cancer cell-targeted drug delivery.
@nl
P2860
P921
P1476
Chimeric aptamers in cancer cell-targeted drug delivery
@en
P2093
Rupinder K Kanwar
P2860
P304
P356
10.3109/10409238.2011.614592
P5008
P577
2011-09-28T00:00:00Z